Background: Carbohydrate antigen 19-9 (CA 19-9) is a representative tumor marker used for the diagnosis of pancreatic and biliary tract cancers. There are few published research results that can be applied to actual clinical practice for ampullary cancer (AC) alone. This study aimed to demonstrate the relationship between the prognosis of AC and the level of CA 19-9, and to determine the optimal thresholds.

Methods: Patients who underwent curative resection (pancreaticoduodenectomy (PD) or pylorus preserving pancreaticoduodenectomy (PPPD)) for AC at the Seoul National University Hospital between January 2000 and December 2017 were enrolled. To determine the optimal cutoff values that could clearly stratify the survival outcome, the conditional inference tree (C-tree) method was used. After obtaining the optimal cutoff values, they were compared to the upper normal clinical limit of 36 U/mL for CA 19-9. Results In total, 385 patients were enrolled in this study. The median value of the tumor marker CA 19-9 was 18.6 U/mL. Using the C-tree method, 46 U/mL was determined to be the optimal cutoff value for CA 19-9. Histological differentiation, N stage, and adjuvant chemotherapy were significant predictors. CA 19-9 36 U/mL had marginal significance as a prognostic factor. In contrast, the new cutoff value, CA 19-9 46 U/mL, was found to be a statistically significant prognostic factor (HR: 1.37, = 0.048).

Conclusions: The new cutoff value of CA 19-9 46 U/mL may be used for evaluating the prognosis of AC. Therefore, it may be an effective indicator for determining treatment strategies such as surgical treatments and adjuvant chemotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136701PMC
http://dx.doi.org/10.3390/cancers15082281DOI Listing

Publication Analysis

Top Keywords

optimal cutoff
16
cutoff 19-9
12
19-9 u/ml
12
19-9
9
ampullary cancer
8
tumor marker
8
determine optimal
8
cutoff values
8
c-tree method
8
adjuvant chemotherapy
8

Similar Publications

Background And Objective: Leucine-rich alpha-2 glycoprotein (LRG) is a novel biomarker for Crohn's disease (CD). The utility of combination use of LRG and C-reactive protein (CRP) has not been reported. This study aimed to investigate the diagnostic performance of LRG in combination with CRP to predict endoscopic activity.

View Article and Find Full Text PDF

Objective: To identify independent risk factors for Henoch-Schönlein purpura nephritis (HSPN) in pediatric patients.

Methods: This study enrolled 180 pediatric patients (90 with HSP, 90 with HSPN) hospitalized at the 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from December 2022 to October 2023, with a follow-up of at least six months. Clinical data were collected at the time of the first onset of HSP.

View Article and Find Full Text PDF

Background: Axillary lymph node metastasis (ALNM) is a significant predictor of overall patient survival; thus, precise evaluation of ALNM is essential for staging breast cancer, informing multimodal treatment strategies, and ensuring optimal patient care. This study aimed to establish a magnetic resonance imaging (MRI) scoring system for predicting extensive axillary nodal metastasis in patients with clinically node-negative breast cancer derived from preoperative breast and axillary MRI.

Methods: This study included 226 patients with clinically node-negative breast cancer who underwent preoperative breast and axillary MRI between January 1, 2010 and December 31, 2020 at King Chulalongkorn Memorial Hospital.

View Article and Find Full Text PDF

Ultrahigh-voltage potassium-ion batteries (PIBs) with cost competitiveness represent a viable route towards high energy battery systems. Nevertheless, rapid capacity decay with poor Coulombic efficiencies remains intractable, mainly attributed to interfacial instability from aggressive potassium metal anodes and cathodes. Additionally, high reactivity of K metal and flammable electrolytes pose severe safety hazards.

View Article and Find Full Text PDF

Introduction: Myelofibrosis (MF) is often characterized by a multifactorial anemia determined, in part, by bone marrow (BM) fibrosis, extramedullary erythropoiesis and splenomegaly. Ruxolitinib (RUX) is the first-in-class janus kinase 2 (JAK2) inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. The red cell distribution width (RDW) is the measure of erythrocyte volume variability (anisocytosis).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!